Renovos is  are pioneering a nanoclay gel technology platform, RENOVITE®, for medical applications to address the unmet need for effective tissue regeneration, offering safer, more economic solutions for health systems, and better outcomes for patients, to help them remain active for longer.
According to Renovos’ chairman, James Otter,
“Equity support from ORUK has been very valuable to a young company like Renovos, because ORUK support, in addition to vital cash, provides external validation from a well-respected, specialist organisation as well as access to new contacts and networks. This support from ORUK endorses the company and so encourages less specialist investors to engage.”
